Search results
UK researchers have discovered that passing a weak electrical current between electrodes on a person’s scalp may lead to a reduction in frequency of the visual hallucinations experienced by some people living with sight loss.
Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.
The latest research news from Retina UK.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
TPT and Sight Loss Councils: Cut it back campaign
The latest research news from Retina UK.
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.
The latest research news from Retina UK.
Inside: Our intrepid Sahara Trek #TeamRetinaUK tell us about their incredible experience. 2026 is now fully underway and we are excited to tell you about our plans. Could you take part in a challenge event or volunteer to do a bucket collection in London for Retina UK?
